4//SEC Filing
Fink Jeffrey Arvin 4
Accession 0001638599-20-000979
CIK 0001535955other
Filed
Dec 16, 7:00 PM ET
Accepted
Dec 17, 4:07 PM ET
Size
7.2 KB
Accession
0001638599-20-000979
Insider Transaction Report
Form 4
Lipocine Inc.LPCN
Fink Jeffrey Arvin
Director
Transactions
- Exercise/Conversion
Common Stock
2020-12-16+5,625→ 6,562 total - Exercise/Conversion
Restricted Stock Unit
2020-12-16+5,625→ 5,625 totalExercise: $0.00From: 2020-12-16Exp: 2027-01-25→ Common Stock (5,625 underlying)
Footnotes (2)
- [F1]Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units.
- [F2]Subject to vesting whereby 1/4 of the shares subject to the award will vest on December 31, 2017 and the remaining 3/4 of the shares subject to the award will vest on the receipt by the Company of FDA approval of TLANDO.
Documents
Issuer
Lipocine Inc.
CIK 0001535955
Entity typeother
Related Parties
1- filerCIK 0001595930
Filing Metadata
- Form type
- 4
- Filed
- Dec 16, 7:00 PM ET
- Accepted
- Dec 17, 4:07 PM ET
- Size
- 7.2 KB